Atorvastatin / Risk Cancer Research Results

ATV, Atorvastatin: Click to Expand ⟱

Features: Statin

Atorvastatin is a statin, i.e., an inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway. Clinically it is prescribed to lower LDL cholesterol and cardiovascular risk.

Atorvastatin — a synthetic small-molecule statin that competitively inhibits HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway. It is a clinically approved oral lipid-lowering drug (LDL-C reduction; ASCVD risk reduction) with extensive hepatic first-pass handling and pleiotropic vascular/anti-inflammatory effects. Classification: small-molecule drug; HMG-CoA reductase inhibitor (statin). Standard abbreviation(s): ATV; (brand: Lipitor). In oncology research, its main leverage is MVA-pathway suppression leading to reduced isoprenoid supply (FPP/GGPP) and impaired prenylation-dependent signaling (Ras/Rho family), with context-dependent chemosensitization/radiosensitization reported in preclinical and limited clinical settings.

Primary mechanisms (ranked):

HMGCR inhibition → ↓ mevalonate flux → ↓ FPP/GGPP isoprenoids → impaired protein prenylation (Ras/Rho/Rac signaling dependence)
↓ prenylation/↓ lipid-raft cholesterol support → attenuation of growth, survival, EMT/migration programs (context-dependent)
Compensatory sterol-feedback rewiring (SREBP2-driven upregulation of MVA genes; “restore-the-pathway” resistance axis)
Immuno-inflammatory modulation (often ↓ NF-κB–linked cytokine programs; tumor-context dependent)
Cell-stress outputs (apoptosis/autophagy modulation; mitochondrial stress/ROS changes in some models)
Therapy interaction phenotypes (chemosensitization and radiosensitization in selected contexts; not universal)

Bioavailability / PK relevance: Oral dosing with high hepatic extraction; exposure is strongly interaction-sensitive because atorvastatin is a CYP3A4 substrate and also uses hepatic transport (e.g., OATP1B1/1B3). Clinically meaningful systemic levels are achievable, but many anticancer in-vitro concentrations may exceed typical free plasma exposures; tumor delivery and intracellular “on-pathway” inhibition are therefore context- and dosing-dependent.

In-vitro vs systemic exposure relevance: Antiproliferative/EMT and apoptosis effects in cell culture are frequently reported at micromolar concentrations, which may be higher than unbound systemic exposures in humans; the most translatable mechanism is on-target MVA suppression with downstream prenylation stress, especially where tumors are MVA-addicted or combined with agents that block feedback/compensation.

Clinical evidence status: Approved drug for dyslipidemia/ASCVD prevention. In cancer: extensive preclinical literature plus observational associations; limited interventional oncology studies exist (including biomarker-focused trials and combination/adjunct concepts). Overall status: repurposing candidate with context-dependent signals; not an established anticancer therapy.

Across preclinical and observational contexts, atorvastatin tends to:
-DOWNREGULATE proliferative and survival signaling (via impaired prenylation)
-REDUCE inflammatory signaling (NF-κB–linked effects)
-MODULATE immune and stromal interactions
-SENSITIZE some tumors to chemotherapy or radiation (context-dependent)

-Epidemiologic studies suggest statin use is associated with reduced incidence or improved outcomes in some cancers (e.g., colorectal, prostate, breast).

Atorvastatin — cancer-relevant mechanistic axes (ranked)

Rank	Pathway / Axis	Cancer Cells	Normal Cells	TSF	Primary Effect	Notes / Interpretation
1	Mevalonate pathway suppression	HMGCR ↓ → MVA flux ↓	HMGCR ↓ (hepatic target)	P/R	Depletes sterols + isoprenoids upstream	On-target mechanism; anticancer relevance rises in MVA-addicted tumors and when combined with strategies that prevent compensation.
2	Protein prenylation stress	Ras/Rho/Rac prenylation ↓ → signaling output ↓	Variable; typically tolerated at clinical doses	R	Disrupts membrane localization of key GTPases	Central downstream effector of anticancer activity; impacts proliferation, migration, cytoskeletal dynamics, and survival programs.
3	SREBP2 feedback and “restore-the-pathway” resistance	SREBP2 ↑ (often) → HMGCR/MVA genes ↑ (adaptive)	SREBP2 ↑ (homeostatic lipid control)	G	Adaptive rewiring that can blunt efficacy	Common translational constraint: tumors may upregulate MVA pathway, increase uptake, or rewire metabolism to bypass blockade.
4	Growth and survival signaling	PI3K–AKT ↔/↓, MAPK ↔/↓ (model-dependent)	Endothelial survival ↔/↑ (context-dependent)	R/G	Downshifts pro-survival signaling tone	Often secondary to prenylation/lipid-raft disruption; direction depends on oncogenic wiring and dose.
5	Migration, invasion, EMT	EMT ↓, motility ↓ (often)	Wound/repair migration ↔	G	Anti-migratory / anti-invasive phenotype	Mechanistically linked to Rho-family prenylation and cytoskeletal/ECM programs; may be clinically relevant in select settings.
6	Inflammation and NF-κB-linked cytokine programs	IL-6/IL-8/TNF-α ↓ (often)	Vascular inflammation ↓	R/G	Anti-inflammatory immunometabolic shift	Pleiotropic statin effects; may affect tumor microenvironment and therapy tolerance, but tumor-immune direction can be context-dependent.
7	ROS and mitochondrial stress	ROS ↑ (sometimes; dose-dependent)	Oxidative injury ↔/↓ in vascular contexts	P/R	Stress signaling that can promote apoptosis or sensitize to therapy	Reported in subsets of models; not universally primary. Separate “cancer cell ROS ↑” from “vascular protective” pleiotropy.
8	Cell death programs	Apoptosis ↑; autophagy ↔/↑ (model-dependent)	Generally cytoprotective at therapeutic dosing	R/G	Stress-induced cell fate shift	Often downstream of prenylation deficit + metabolic stress; strong effects often require higher concentrations or combinations.
9	Drug transport and resistance	P-gp ↓ (reported); efflux ↔/↓ (context-dependent)	Transporter effects ↔	R/G	Potential bioenhancement / chemosensitization	May contribute to combination effects, but clinical relevance is uncertain and interaction risk must be managed.
10	Radiosensitization and chemosensitization	RadioS ↑; ChemoSen ↑ (subset)	Normal tissue injury ↔/↓ (some contexts)	G	Adjunct therapy leverage (context-dependent)	Signals exist in preclinical and limited clinical/biomarker work; not a class-wide guarantee and may depend on tumor MVA reliance.
11	Clinical Translation Constraint	Free exposure may be below many in-vitro “kill” concentrations; adaptive SREBP2 feedback; tumor heterogeneity	Myopathy/rhabdomyolysis risk ↑ with interacting drugs; hepatic enzyme elevations; pregnancy contraindication	—	Defines practical therapeutic window	Major constraints: CYP3A4/transport interactions (e.g., strong inhibitors; grapefruit), muscle toxicity risk, and uncertain tumor delivery/on-target engagement at tolerated doses.

TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr

Risk, Risk: Click to Expand ⟱

Source:

Type:

Risk: by definition reduces risk of disease or cancer.
Down Target direction of risk indicates lower cancer risk.
ChemoPreventive also mean lower cancer risk. But for Chemopreventive an up arrow indicates more preventive.

Cancer Risk Impact Score (CRIS)
CRIS scale:
–5 = very strong risk reduction
–4 = strong risk reduction
–3 = moderate risk reduction
–2 = modest risk reduction
–1 = weak / context-dependent
0 = neutral


CRIS  Exposure / Compound  Evidence  Cancers  Notes


-5  Exercise (overall)
VStrong Hum  BC, CRC, Endo, PCa, Liv
↓insulin/IGF-1, ↓inflammation, ↑immune surveillance, ↓hormones



-5  Aerobic + resistance  VStrong Hum  Broad inc + mort
Best overall exercise synergy



-4  Aerobic exercise (mod–vig)  VStrong Hum  BC, CRC, Endo
Dose–response; ↓visceral fat



-4  Resistance training (alone)  Strong Hum  BC, CRC
↑insulin sensitivity; ↑lean mass



-3  High-intensity interval training  Mod–Strong Hum  BC, CRC
↑AMPK; ↑mitochondrial function; adherence matters



-2  NEAT / low-intensity activity  Moderate Hum  CRC
↓sedentary harm



-5  Cruciferous vegetable pattern  Strong Hum  Lung, CRC, BC, PCa
↑NRF2, ↓CYP1; ITC synergy



-5  Sunlight exposure (physiologic)  Strong Hum  CRC, BC, PCa
↑circadian alignment, ↑immune effects beyond vitamin D



-4  Fasting (metabolic pattern)
Strong Mech + Hum  BC, CRC, PCa 
↓IGF-1, ↓mTOR, ↑autophagy



-4  Curcumin
Hum + Pre  GI, BC, PCa
↓NF-κB, ↓STAT3



-4  Sulforaphane
Hum + Pre  Lung, CRC, BC
↑NRF2, ↓HDAC



-4  PEITC
Hum + Pre  Lung, CRC, PCa
↓CYP1A2, ↑apoptosis



-4  EGCG (tea matrix)
Strong Hum  GI, PCa, BC
↓angiogenesis; tea matrix superior to extract



-4  Lycopene
Strong Hum  PCa
↓oxidative DNA damage



-4  Apigenin
Pre + Diet Hum  BC, PCa, CRC 
↓PI3K-AKT, ↑p53



-4  Luteolin
Pre + Diet Hum  Lung, CRC, BC 
↓STAT3, ↓EMT



-4  Kaempferol
Diet Hum  Ov, Panc, Lung
↓VEGF, ↑apoptosis



-4  Fisetin
Pre + Early Hum  CRC, PCa, Mel
↓mTOR; senolytic activity



-4  Ellagic acid → Urolithin A
Hum (microbiome)  CRC, PCa, BC
↑mitophagy, ↓ER/AR signaling



-3  Omega-3 (EPA/DHA)
Strong Hum  CRC, BC
↓inflammation, ↓COX-2



-3  Vitamin D3 (supp)
Obs + RCT  CRC, BC
U-shaped response; ↓proliferation



-3  Garlic (allicin)
Mod Hum  GI
↓inflammation, ↓H. pylori



-3  Mushroom beta-glucans
Hum adjunct  GI, BC
↑NK cells, ↑immune surveillance



-3  Melatonin
Hum + Mech  BC, PCa
↓estrogen signaling, ↑circadian regulation



-3  Coffee (whole)
Strong Hum  Liv, Endo
↓fibrosis, ↓inflammation



-2  Quercetin
Limited Hum  Lung, CRC
Senolytic; ↓PI3K signaling



-2  Resveratrol
Limited Hum  CRC, BC
↓NF-κB; low bioavailability



-2  I3C / DIM
Mod Hum  BC, Cerv
↑2-OH estrogen, ↓ER signaling



-2  Thymoquinone
Early Hum  BC, CRC
↑apoptosis, ↓NF-κB



-2  Beta-carotene (food)
Hum  Lung
Antioxidant only in whole-food context



-1  Vitamin K2 (MK-4/7)
Limited Hum  Liv, PCa
↓proliferation, ↑differentiation



-1  Boron
Obs  PCa, Lung
↓inflammation; hormone modulation



0  Vitamin C (oral)
Strong Hum  —
Neutral overall effect



0  Genistein (soy)
Strong Hum  BC, PCa
Timing-dependent effects



0  Selenium (diet)
Mixed Hum  PCa
Narrow therapeutic window



0  Capsaicin
Mixed  Gastric
Dose-dependent effects



+2  Vitamin E (alpha only)
Strong RCT  PCa
Increased risk signal



+2  Green tea extract (high-dose)
Case reports  Liv
Hepatotoxicity reported



+4  Beta-carotene (supplement)
Strong RCT  Lung (smokers)
Increased lung cancer risk in smokers



+5  Alcohol (ethanol)
Strong Hum  BC, Liv, Eso
Linear increase in cancer risk




Evidence
Hum        human data
VStrong    very strong
Strong     strong
Mod        moderate
Obs        observational
Pre        preclinical
RCT        randomized controlled trial
Mech       mechanistic
Adjunct    adjunct clinical use

Scientific Papers found: Click to Expand⟱

5449-

ATV,

Pleiotropic effects of statins: A focus on cancer

NA,

Var,

lipid-P↓, TumCG↓, Apoptosis↑, ChemoSen↑, RAS↓, HMG-CoA↓, HMGCR↓, LDL↓, toxicity↓, Risk↓, P21↑, HDAC↓, Bcl-2↓, BAX↑, BIM↑, Casp↑, cl‑PARP↑, MMP↓, ROS↑, angioG↓, TumMeta↓, PTEN↑, eff↑, OS↑, Remission↑,

5447-

ATV,

The Mevalonate Pathway, a Metabolic Target in Cancer Therapy

Review,

Var,

Risk↓, Dose↑, ChemoSen↑, chemoP↑, HMG-CoA↓, EMT↓, CSCs↓, HH↝, YAP/TEAD↝,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: Risk, Risk

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:2  Target#:785  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

Atorvastatin / Risk Cancer Research Results

Atorvastatin — cancer-relevant mechanistic axes (ranked)

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

Mitochondria & Bioenergetics ⓘ

Core Metabolism/Glycolysis ⓘ

Cell Death ⓘ

DNA Damage & Repair ⓘ

Cell Cycle & Senescence ⓘ

Proliferation, Differentiation & Cell State ⓘ

Migration ⓘ

Angiogenesis & Vasculature ⓘ

Drug Metabolism & Resistance ⓘ

Functional Outcomes ⓘ

Pathway results for Effect on Normal Cells:

Home Page